NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Veradermics, Incorporated MANE

Veradermics, Incorporated listed on NYSE on 4 Feb 2026 and is not in the S&P 500. It is worth $5.2 billion. Its board has 7 directors, 6 of them independent. 5 other officers are on file. At 30 Jun 2026, Montanova Capital was its largest institutional holder, with 9.9% of the company.

CEO
Reid Alexander Waldman
Listed
4 Feb 2026 on NYSE, IPO filings and terms
Headquarters
New Haven, CT
Market cap
$5.2B
19 Nov 2026 close
Revenue
-
No annual report yet

Board and leadership

Board and officers

Board from the proxy filed 30 Mar 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (7)
Reid Alexander WaldmanChief Executive OfficerNot independent 路 since 2019Chief Executive Officer2019No31
John W. ChildsDirectorIndependent 路 since 2021 路 Audit, CompensationChairman, J.W. Childs Associates, L.P.Other boards: Biohaven Ltd.Director2021YesAudit, Compensation84
Vlad CoricDirectorIndependent 路 since 2021 路 Compensation (chair)Chief Executive Officer, Biohaven Ltd.; Clinical Professor, Yale School of MedicineOther boards: Biohaven Ltd. and Royalty Pharma plcDirector2021YesCompensation (chair)55
Patrick G. EnrightDirectorIndependent 路 since 2024 路 Audit (chair)Managing Director, Longitude Capital Management Co., LLCOther boards: BioAge Labs, Jazz Pharmaceuticals PLC, Vera Therapeutics and Zenas BioPharmaDirector2024YesAudit (chair)64
David Matthew FriedmanDirectorIndependent 路 since 2025 路 Nominating and Corporate GovernanceManaging Director and Senior Analyst, Suvretta Capital Management, LLCDirector2025YesNominating and Corporate Governance51
Jane M. Grant-KelsDirectorIndependent 路 since 2021 路 Compensation, Nominating and Corporate Governance (chair)Vice Chair of the Department of Dermatology, Founding Director of the Cutaneous Oncology Center and Melanoma Programs and Professor of Dermatology, Pathology and Pediatrics, University of Connecticut Health CenterDirector2021YesCompensation, Nominating and Corporate Governance (chair)76
Katarina PanceDirectorIndependent 路 since 2025 路 Audit, Nominating and Corporate GovernanceSenior Associate, SR One Capital ManagementDirector2025YesAudit, Nominating and Corporate Governance29
Officers (5)
Dominic Gabriel CarranoChief Financial OfficerLast filed 5 Feb 2026Chief Financial Officer
Timothy August DursoChief Technical OfficerLast filed 18 Aug 2026Chief Technical Officer
Michael V. GrecoGeneral CounselLast filed 5 Feb 2026General Counsel
David HollanderChief R&D OfficerLast filed 3 Sep 2026Chief R&D Officer
Mark NeumannChief Commercial OfficerLast filed 5 Feb 2026Chief Commercial Officer

Owners and trading

Largest institutional holders

Each fund group's share of Veradermics, Incorporated. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 32.4% of Veradermics, Incorporated.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $97.9 million of stock in 4 sales and bought $35.8 million in 6 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
11 Nov 2026SalePatrick G. EnrightDirectorDirectorSale500,000$75M
17 Aug 2026SaleReid Alexander WaldmanChief Executive OfficerChief Executive OfficerSale67,500$7.3M
17 Aug 2026SaleTimothy August DursoChief Technical OfficerChief Technical OfficerSale43,500$4.7M
12 Aug 2026SaleJohn W. ChildsDirectorDirectorSale100,000$11M
6 Feb 2026BuyAaron CowenDirectorDirectorBuy30,521$1.1M
5 Feb 2026BuyPatrick G. EnrightDirectorDirectorBuy1,075,000$18M
5 Feb 2026BuyJohn W. ChildsDirectorDirectorBuy294,117$5.0M
5 Feb 2026BuyAaron CowenDirectorDirectorBuy96,200$3.7M
5 Feb 2026BuyVlad CoricDirectorDirectorBuy117,646$2.0M
4 Feb 2026BuyAaron CowenDirectorDirectorBuy155,953$5.8M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

4 large insider sales in the last two years.

Left the company or board 0Appointed 0WARN layoff notices 0Large insider sales 4Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Veradermics, Incorporated's insider sales.

Events, newest first

Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.